{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:10:48Z","timestamp":1793686248388,"version":"4.5.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40265-021-01591-1","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:02:49Z","timestamp":1630404169000},"page":"1671-1675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":197,"title":["Telitacicept: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"1591_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fmed.2021.655100","volume":"8","author":"SN Liossis","year":"2021","unstructured":"Liossis SN, Staveri C. What\u2019s new in the treatment of systemic lupus erythematosus. Front Med. 2021;8:221.","journal-title":"Front Med"},{"issue":"4","key":"1591_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/art.40396","volume":"70","author":"S Karrar","year":"2018","unstructured":"Karrar S, Cunninghame Graham DS. Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol. 2018;70(4):496\u2013507.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1591_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.coi.2012.10.004","volume":"24","author":"J Choi","year":"2012","unstructured":"Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus: an update. Curr Opin Immunol. 2012;24(6):651\u20137.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"1591_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12519-019-00229-3","volume":"16","author":"L Pan","year":"2020","unstructured":"Pan L, Lu MP, Wang JH, et al. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020;16(1):19\u201330.","journal-title":"World J Pediatr"},{"issue":"18","key":"1591_CR5","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1097\/CM9.0000000000000983","volume":"133","author":"Y Fan","year":"2020","unstructured":"Fan Y, Hao YJ, Zhang ZL. Systemic lupus erythematosus: year in review 2019. Chin Med J (Engl). 2020;133(18):2189\u201396.","journal-title":"Chin Med J (Engl)"},{"key":"1591_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TCRM.S252592","volume":"17","author":"A Bag-Ozbek","year":"2021","unstructured":"Bag-Ozbek A, Hui-Yuen JS. Emerging B-cell therapies in systemic lupus erythematosus. Ther Clin Risk Manag. 2021;17:39\u201354.","journal-title":"Ther Clin Risk Manag"},{"key":"1591_CR7","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.ejps.2021.105704","volume":"159","author":"X Yao","year":"2021","unstructured":"Yao X, Ren Y, Zhao Q, et al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021;159:105704.","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"1591_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jcph.686","volume":"56","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Chen X, Hou Y, et al. Pharmacokinetics, pharmacodynamics, safety, and clinical activity of multiple doses of RCT-18 in Chinese patients with systemic lupus erythematosus. J Clin Pharmacol. 2016;56(8):948\u201359.","journal-title":"J Clin Pharmacol"},{"key":"1591_CR9","unstructured":"Remegen. Telitacicept: NMPA approval on 9th March. 2021. http:\/\/www.remegen.com\/Project.aspx?ClassID=21#ttxp. Accessed 28 Jun 2021."},{"key":"1591_CR10","volume-title":"Telitacicept: Chinese prescribing information","author":"Remegen","year":"2021","unstructured":"Remegen. Telitacicept: Chinese prescribing information. Yantai: Rongchang Biopharmaceutical (Yantai) Co., Ltd; 2021."},{"key":"1591_CR11","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22438.1","author":"S Yung","year":"2020","unstructured":"Yung S, Yap DY, Chan TM. A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. F1000Res. 2020. https:\/\/doi.org\/10.12688\/f1000research.22438.1.","journal-title":"F1000Res."},{"issue":"1","key":"1591_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bcp.12908","volume":"82","author":"X Chen","year":"2016","unstructured":"Chen X, Zhao Q, Hou Y, et al. Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS\/APRIL fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2016;82(1):41\u201352.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 10","key":"1591_CR13","first-page":"5262","volume":"71","author":"D Wu","year":"2019","unstructured":"Wu D, Li J, Xu D, et al. A human recombinant fusion protein targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (April), telitacicept (RC18), in systemic lupus erythematosus (SLE): results of a phase 2b study [abstract no. L18]. Arthritis Rheumatol. 2019;71(Suppl 10):5262\u20134.","journal-title":"Arthritis Rheumatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01591-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01591-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01591-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T19:09:29Z","timestamp":1634324969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01591-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":13,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1591"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01591-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"31 August 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Format errors","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}